Clinigen Group (LON:CLIN) target price held steady at 1,000.00GBX, reported today by Peel Hunt
- Updated: December 1, 2016
Just yesterday Clinigen Group (LON:CLIN) traded -2.52% lower at 739.00GBX. Clinigen Group’s 50-day moving average is 742.07GBX and its 200-day moving average is 649.72GBX. The last stock price is up 13.26% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 427,843 shares of CLIN traded hands, down from an average trading volume of 482,921
Clinigen Group (LON:CLIN) had its target price hold steady to 1,000.00GBX by Peel Hunt in a report released Thursday December 01, 2016. The new target price indicates a possible upside of 0.35% based on the company's last stock close price.
Previously on 3/02/2016, Stifel released a statement about Clinigen Group (LON:CLIN) held steady the target price at 800.00GBX. At the time, this indicated a possible upside of 0.22%.
Recent Performance Chart
Clinigen Group has 52 week low of 492.75GBX and a 52 week high of 793.50GBX with a PE ratio of 62.36 and has a market capitalization of 0 GBX.
Also covering Clinigen Group's price target, a total of 5 analysts have reported on the stock. The consensus target price is 850.00GBX with 3 equity analysts rating the company a strong buy, two equity analysts rating the company a buy, 0 brokers rating the stock a hold, 0 brokers rating the company a underperform, and lastly zero brokerages rating the company a sell.
General Company Details For Clinigen Group (LON:CLIN)
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.